CANNABINOIDS AND PARKINSON’S DISEASE

DEWM FILES PAPERWORK TO SECURE INTELLECTUAL PROPERTY RELATED TO CANNABINOIDS AND PARKINSON’S DISEASE NEW ORLEANS, LA – (Marketwired - Jul 24, 2017)

Dewmar International BMC, Inc. today announced that it has filed documents with the United States Patent and Trademark Office for the treatment of Parkinson’s disease with cannabinoids. Medical Marijuana has over 100 molecules or cannabinoids within the plant that in the right combinations or using the right delivery methods, can be used to treat anything from cancer to Parkinson’s disease. It is Dewmar’s goal to utilize the experience and the education of its CEO, Marco Moran DPh, MBA to commercialize its intellectual property assets related to marijuana and most importantly, the precise delivery of medical marijuana and its constituents and/or byproducts to bring a new era in targeted therapeutics to improve patient care and outcomes. Marco Moran, CEO of Dewmar International, commented, “Research suggests two problems persist with medicines used to treat Parkinson’s disease today; 1) low metabolic absorption of the medicine by the human body and 2) severe side effects. Cannabinoids may prove to be more effective in some instances with fewer side effects when compared to common medicines used to treat Parkinson’s disease. So, our goal is to utilize our patent pending technology to deliver effective cannabinoids to Parkinson’s patients with a rapid onset of action and high bioavailability. This is the essence of the intellectual property that we are seeking to protect.”